Evaluation of heterogeneity in pharmacotherapy trials for drug dependence: A bayesian approach

American Journal of Drug and Alcohol Abuse

Volumn 35, Issue 2, 2009, Pages 95-102

  Green, C E ^a   Moeller, F G ^b   Schmitz, J M ^b   Lucke, J F ^a   Lane, S D ^b   Swann, A C ^b   Lasky, R E ^a   Carbonari, J P ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

Bayesian; Cocaine dependence; Substance abuse

Indexed keywords

CITALOPRAM; COCAINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; BAYES THEOREM; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; EVALUATION; HUMAN; IOWA GAMBLING TASK; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT RESPONSE; PATHOLOGICAL GAMBLING; PSYCHOLOGICAL ASPECT;

BAYES THEOREM; CITALOPRAM; COCAINE-RELATED DISORDERS; DECISION MAKING; DOUBLE-BLIND METHOD; GAMBLING; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 65549088592     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990802647503     Document Type: Article

References (50)

1. de Lima MS, de Oliveira Soares BG, Pereira Reisser AA, Farell M. Pharmacological treatment of cocaine dependence: A systematic review. Addiction 2002; 97:931-949.
2. de Lima MS, de Oliveira Soares BG, Pereira Reisser AA, Farell M. Pharmacological treatment of cocaine dependence: a systematic review. Addiction 2002; 97:931-949.
3. Elkashev A, Vocci F. Biological markers of cocaine addiction: Implications for medications development. Addict Biol 2003; 8:123-139.
4. Carroll KM, Nich C, Rounsaville BJ. Variability in treatment-seeking cocaine abusers: Implications for clinical pharmacotherapy trials. NIDA Res Monogr 1997; 175:137-157.
5. Nunes EV. Methodologic recommendations for cocaine abuse clinical trials: A clinician-researcher's perspective. NIDA Res Monogr 1997; 175:73-95.
6. Elkashef A, Holmes TH, Bloch DA, Shoptaw S, Kampman K, Reid MS, Somoza E, Ciraulo D, Rotrosen J, Leiderman D, Montgomery A, Vocci F. Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. Addiction 2005; 100(Supplement. 1):91-101.
7. Hernandez AV, Boersma E, Murray GD, Habbema JDF, Steyerberg EW. Subgroup analyses in therapeutic cardiovascular clinical trials: Are most of them misleading? Am Heart J 2006; 151:257-264.
8. Counsell CE, Clarke MJ, Slattery J, Sandercock PAG. The miracle of DICE therapy for acute stroke: Fact or fictional product of subgroup analysis? British Med J 1994; 309:1677-1681.
9. ISIS-2 Collaborative Group. Randomized trial of IV streptokinase, oral aspirin, both, or neither among 17187 cases of suspected myocardial infarction. Lancet 1988; 2:349-360.
10. Feinstein AR. The problem of cogent subgroups: A clinicostatistical tragedy. J Clin Epidemiol 1998; 51(4):297-299.
11. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized controlled trials: Quantifying the risks of false-positives and false negatives. Executive Summary. Health Technol Assess 2001; 5(33):1-4.
12. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355:1064-1069.
13. Pocock SJ,Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems. Stat Med 2002; 21:2917-2930.
14. Rothwell PM. Treating Individuals 2: Subgroup analysis in randomized controlled trials: Importance, indications, and interpretations. Lancet 2005; 365:176-186.
15. Brookes ST,Whitely E, EggerM, Smith GD, Mulheran PA, Peters TJ. Subgroup Analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for interaction tests. J Clin Epidemiol 2004; 57: 229-236.
16. Adams KF. Post hoc subgroup analysis and the truth of a clinical trial. Am Heart J 1998; 136(5):753-758.
17. Cook DI, Gebski VJ, Keech AC. Subgroup analysis in clinical trials. Med J Aust 2004; 180:289-291.
18. Guillemin F. Primer: The fallacy of subgroup analysis. Nat Clin Pract Rheumatology 2007; 3(7):407-413.
19. Dixon DO, Simon R. Bayesian Subset Ańalysis. Biometrics 1991; 47:871-881.
20. Simon R, Freedman LS. Bayesian design and analysis of twoXtwo factorial clinical trials. Biometrics 1997; 53:456-464.
21. Simon R, Dixon DO, Freidlin B. Bayesian subset analysis of a clinical trial for the treatment of HIV infections. In Bayesian Biostatistics (Statistics: a Series of Textbooks and Monographs). Donald Berry and Dalene Stangl, eds. Marcel Dekker, New York (1996).
22. Simon R. Bayesian subset analysis: Application to studying treatment-bygender interactions. Stat Med 2002; 21:2909-2916.
23. Goodman SN. Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy. Ann Intern Med 1999; 130:995-1004.
24. Johnstone DJ. Tests of significance in theory and practice. Statistician. 1986; 35:491-504.
25. Lucke JF. 'Fall prevention programs for the elderly: A Bayesian secondary meta-analysis.' Canadian J. Nurs Res 2004; 36(3):48-64.
26. Howson C, Urbach P. Scientific reasoning: The Bayesian approach, Open Court, Chicago (2006).
27. Firebaugh G.Will Bayesian InferenceHelpASkepticalView. Sociological Methodol 1995; 25: 469-472.
28. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. John Wiley & Sons Ltd. West Sussex, England (2004).
29. Kadane JB. 'Prime time for Bayes.' Control Clin Trials 1995; 16:313-318.
30. Hacking I. An introduction to probability and inductive logic, Cambridge University Press, Cambridge (2001).
31. Shimony A. 'Scientific inference' In Search for a naturalistic world view: Scientific method and epistemology, Cambridge University Press, Cambridge, UK (1993).
32. Moeller FG, Schmitz JM, Steinberg JL, Green CM, Reist C, Lai LY, Swann AC, Grabowski J. Citalopram combined with behavioral therapy reduces cocaine use: A double-blind placebo controlled trial. Am J Drug Alcohol Abuse 2007; 33(3):367-378.
33. Bechara A, Damasio H. Decision-making and addiction (part I): Impaired activation of somatic states in substance dependent individuals when pondering decisions with negative future consequences. Neuropsychologia 2002; 40:1675-1689.
34. Stout JC, Busemeyer JR, Lin A, Grant SJ, Bonson KR. Cognitive modeling analysis of decision-making processes in cocaine abusers. Psychon Bull Rev 2004; 11(4):742-747.
35. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. Am J Psychiatry 2001; 158:1783-1793.
36. Coffey SF, Gudleski GD, Saladin ME, Brady KT. Impulsivity and rapid discounting of delayed hypothetical rewards in cocaine-dependent individuals. Exp Clin Psychopharmacol 2003; 11:18-25.
37. Patkar AA, Murray HW, Mannelli P, Gottheil E, Weinstein SP, Vergare MJ. Pre-treatment measures of impulsivity, aggression and sensation seeking are associated with treatment outcome for African-American cocaine dependent patients. J Addict D/s 2004; 23:109-122.
38. Peroutka SJ. Serotonin receptor variants in disease: New therapeutic opportunities? Ann NY Acad Sci 1998; 861:16-25.
39. GothertM, Propping P, BonischH, Bruss M, Nothen MM. Genetic variation in human 5-HT receptors: potential pathogenetic and pharmacological role. Ann NY Acad Sci 1998; 861:26-30.
40. Cravchik A, Goldman D. Neurochemical individuality: Genetic diversity among human dopamine and serotonin receptors and transporters. Arch Gen Psychiatry 2000; 57:1105-1114.
41. Bjork JM, Moeller FG, Dougherty DM, Swann AC, Machado MA, Hanis CL. Serotonin 2a receptor T102C polymorphism and impaired impulse control. Am J Med Genet 2002; 14:336-339.
42. Glatt CE, Tampilic M, Christie C, DeYoung J, Freimer NB. Re-screening serotonin receptors for genetic variants identifies population and molecular genetic complexity. Am J Med Genet B Neuropsychiatr Genet 2004; 124:92-100.
43. Patkar AA, Mannelli P, Peindl K, Hill KP, Gopalakrishnan R, Berrettini WH. Relationship of disinhibition and aggression to blunted prolactin response tometa-chlorophenylpiperazine in cocaine-dependent patients. Psychopharmacology (Be/t) 2006; 1-10.
44. Mannelli P, Patkar AA, Peindl K, Tharwani H, Gopalakrishnan R, Hill KP, Berrettini WH. Polymorphism in the serotonin transporter gene and moderators of prolactin response to meta-chlorophenylpiperazine in African- American cocaine abusers and controls. Psychiatry Res 2006; 144:99-108.
45. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 2005; 57:1-26.
46. Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, O'Brien CP. A pilot trial of topirimate for the treatment of cocaine dependence. Drug Alcohol Depend 2004; 75:233-240.
47. Bechara A, Damasio H, Tranel D, Damasio AR. Deciding advantageously before knowing the advantageous strategy. Science 1997; 275:1293-1295.
48. SAS Institute Inc. Preliminary Capabilities for Bayesian Analysis in SAS/STATR Software. Cary, NC: SAS Institute Inc (2006).
49. Ramsey FP. Truth and Probability. In Ramsey, F.P. (1931). The Foundations of Mathematics and other Logical Essays, Ch. VII, p. 156-198.
50. R.B. Braithwaite, ed., London: Kegan, Paul, Trench, Trubner & Co., New York: Harcourt, Brace and Company (1926).